Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina

Hoffmann-La Roche75 enrolled

Overview

This observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (Erivedge) in Argentine patients. Only patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) will be considered in the effectiveness analysis. Study duration is estimated to be approximately 12 months.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Basal Cell Carcinoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Argetine patients prescribed vismodegib according to standard of care and in line with Summary of Product Characteristics (SPC) and local labeling * Diagnosis of laBCC or mBCC for the effectiveness analysis Exclusion Criteria: * None specified

Outcomes

Primary Outcomes

Response rate as assessed by the treating physician

Time frame: Approximately 12 months

Secondary Outcomes

Duration of treatment

Time frame: Approximately 12 months

Duration of response as assessed by the treating physician

Time frame: Approximately 12 months

Incidence of adverse events

Time frame: Approximately 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.